Recommended maintenance doses are 5 mg, 10 mg, or 15 mg once weekly, and 15 mg is the maximum
Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review
Cano A, Chedraui P, Goulis DG, Lopes P, Mishra G, Mueck A, et al
Specific triggers for medical consultation include achieving less than 5% body weight reduction after reaching the maintenance dose (for Wegovy, after 12 weeks at 2.4 mg as per FDA labeling), prolonged weight loss plateau despite adherence, or intolerable side effects preventing dose escalation to therapeutic levels
Study Selection Criteria To be included in the systematic review, a study had to 1) be performed in adults that developed HALT requiring treatment, combined cases of other organs were not included, and 2) have full text available in English
Practical Considerations for Starting GLP-1 Medication Preparation before your first dose is essential for a smooth initiation of GLP-1 therapy